voxilaprevir hcv ns3 4a protease inhibitor chronic hcv after selected prior daa failure us fda approved in the fixed dose vosevi rescue regimen (Gilead Sciences)
Structured Review

Voxilaprevir Hcv Ns3 4a Protease Inhibitor Chronic Hcv After Selected Prior Daa Failure Us Fda Approved In The Fixed Dose Vosevi Rescue Regimen, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 97/100, based on 178 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fix/Vosevi/pmc13748950-6-0-17
Average 97 stars, based on 178 article reviews
Images
1) Product Images from "Therapeutic and Prophylactic Agents for Viral Diseases: Current Status, Challenges, and Future Prospects"
Article Title: Therapeutic and Prophylactic Agents for Viral Diseases: Current Status, Challenges, and Future Prospects
Journal: MedComm
doi: 10.1002/mco2.71024
Figure Legend Snippet: Chemical structures, molecular targets, and regulatory status of small‐molecule antivirals.
Techniques Used: Protease Inhibitor
Related Articles
other:Article Title: [Rational use of modern substances for the treatment of HIV-infection]. Article Snippet: Treatment options for HIV-infection have been improved significantly.. Drugs with new modes of action have been licensed (integrase inhibitor and CCR5-inhibitor) as well as drugs within the existing classes, but improved activity in case of resistance (e.g. darunavir, tipranavir, etravirin).. The treatment goal today is complete and durable suppression of viral replication in treatment-naïve as well as pre-treated patients. |